Drug Bill To Change ANDA Petition Process

Law360, New York (May 10, 2007, 12:00 AM EDT) -- A bipartisan amendment added to a bill renewing drug user fees that passed the U.S. Senate Wednesday would alter the citizen petition process for Abbreviated New Drug Applications, making it harder for brand-name drug makers to use "frivolous" petitions as a way to delay generic drugs, advocates say.

If made law, the amendment, which was sponsored by a bipartisan group of legislators including Sens. Debbie Stabenow (D-MI) and Trent Lott (R-Miss.), would mean that the U.S. Food and Drug Administration would no longer stop the approval...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.